Targeted Genetics Corporation, a clinical-stage biotechnology company, engages in the research and development of gene therapy products and technologies for the treatment of acquired and inherited diseases. Its products include tgAAC94, a Phase I/II trial product for the treatment of inflammatory arthritis and other inflammatory diseases; and tgAAC09, a Phase II clinical product, which is used for the treatment of HIV/AIDS. The company also engages in the development, manufacture, and clinical evaluation of AAV-based therapies with Celladon’s portfolio of genes and cardiovascular expertise for the treatment of congestive heart failure. In addition, Targeted Genetics provides novel...